Pfizer: Esophageal Neoplasms trials
The registry lists 12 Esophageal Neoplasms studies with Pfizer as lead sponsor. 4 are open to participants now and 5 have results posted.
Phase 1 10Phase 2 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.RecruitingNCT07903415Phase 1
- Phase 1 Study of PF-08046033 in Advanced Solid TumorsRecruitingNCT07519655Phase 1
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 1
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersActive, not recruitingNCT04430738Phase 2Results posted
- Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.TerminatedNCT04171141Phase 1Results posted
- Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02001623Phase 1/2Results posted
- A Study of SGN-STNV in Advanced Solid TumorsTerminatedNCT04665921Phase 1
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
- Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.TerminatedNCT04152018Phase 1